Alice Newcombe-Ellis
board of directors @ Mogrify
Alice Newcombe-Ellis is a Series A investor at Mogrify focused on Software and Biotechnology. Alice Newcombe-Ellis is Founding and Managing Partner at Ahren Innovation Capital.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alice Newcombe-Ellis invests in
Stages Alice Newcombe-Ellis invests in
Countries Alice Newcombe-Ellis invests in
Investment Focus
Industry
- Software 2 (17%)
- Biotechnology 2 (17%)
- Information Technology 2 (17%)
- Artificial Intelligence 2 (17%)
- Mineral 1 (8%)
Stage
- Series A 5 (42%)
- Series B 3 (25%)
- Seed 1 (8%)
- Pre-Seed 1 (8%)
- Convertible Note 1 (8%)
Country
- United States 6 (50%)
- United Kingdom 2 (17%)
- Israel 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Heirloom
|
Heirloom is a provider of direct air capture technology to enhance the natural process of CO2 absorption from the atmosphere. Its technology accelerates limestone's ability to capture carbon dioxide, storing it permanently underground while operating with renewable energy. | $150M / Series B / Dec 04, 2024 | |
Rubedo Life Sciences
|
Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $40M / Series A / Apr 22, 2024 | |
Ambi Robotics
|
Ambi Robotics is an artificial intelligence (AI) and robotics company developing advanced solutions that scale e-commerce operations to meet demand while empowering humans to work smarter. The company was founded in 2018 and is based in Berkeley, California, United States. | $32M / Series A / Oct 14, 2022 | |
|
Ambi Robotics
|
Ambi Robotics is an artificial intelligence (AI) and robotics company developing advanced solutions that scale e-commerce operations to meet demand while empowering humans to work smarter. The company was founded in 2018 and is based in Berkeley, California, United States. | $32M / Convertible Note / Oct 14, 2022 | |
AI21 Labs
|
AI21 Labs is a creator of generative artificial intelligence and massive language models, as well as tools for creating artificial intelligence systems with extraordinary understanding and generation of natural language. The company's tool captures real intelligence and rewrites writing to say exactly what is meant; it transforms the waypeople read and write, empowering them in the process; it is an artificial intelligence-based writing companion that understands context and meaning; and it helps people read more efficiently by providing summaries, allowing customers to understand, analyze, and visualize abstract knowledge structures. | $64M / Series B / Jul 12, 2022 | |
|
Heirloom
|
Heirloom is a provider of direct air capture technology to enhance the natural process of CO2 absorption from the atmosphere. Its technology accelerates limestone's ability to capture carbon dioxide, storing it permanently underground while operating with renewable energy. | $53M / Series A / Mar 17, 2022 | |
New Culture
|
New Culture is a food and beverage company that focuses on revolutionizing how cheese is made. It was founded in 2018 and headquartered in San Francisco, California. | $25M / Series A / Nov 22, 2021 | |
Adrestia Therapeutics
|
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells | $232.6M / Series A / Dec 18, 2020 | |
Zapata Quantum
|
Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials.Zapata Computing is a spun out of Harvard Universitylaunched by a group of Harvard scientists, including Alán Aspuru-Guzik.The company was founded in 2017 and is headquartered in Boston, Massachusetts. | $38M / Series B / Nov 19, 2020 | |
Nu Quantum
|
Nu Quantum is a telecommunications company that develops end-to-end quantum cryptography systems.It secures communications within and between cities through urban and satellite free-space optical links. The system helps with the realization of commercial deliverable photonic technologies by combining novel materials and semiconductor technology.This enables clients to secure the exchange of cryptographic keys for the ultra-sensitive detection of light.Yuri Andersson, Mete Atatüre, and Carmen Berraquero founded Nu Quantum in Cambridge, Cambridgeshire in 2018. | $2.7M / Seed / Oct 05, 2020 | |
| See all 12 investments → | |||
Co-Investors
About Mogrify
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.
Mogrify Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alastair Kilgour
Investment Director
|
|||
|
Alice Newcombe-Ellis
board of directors
|
|||
Joe Foster
Chief Operating Officer
|
|||
Jonathan Appleby
Chief Scientific Officer
|
|||
Jose Polo
Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alice Newcombe-Ellis invest in?
Alice Newcombe-Ellis invests primarily in Software, Biotechnology and Information Technology startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alice Newcombe-Ellis last invest?
The most recent investment recorded for Alice Newcombe-Ellis closed in Dec 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
